CINECA IRIS Institutional Research Information System

VOENA, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.618
EU - Europa 1.706
AS - Asia 816
AF - Africa 28
OC - Oceania 8
SA - Sud America 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.182
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.587
CN - Cina 495
IT - Italia 388
SE - Svezia 231
IE - Irlanda 205
UA - Ucraina 149
DK - Danimarca 144
FR - Francia 133
DE - Germania 120
FI - Finlandia 99
SG - Singapore 97
AT - Austria 72
KR - Corea 68
GB - Regno Unito 49
IN - India 38
PL - Polonia 37
JP - Giappone 35
VN - Vietnam 35
CA - Canada 28
BE - Belgio 24
SN - Senegal 24
ES - Italia 16
TR - Turchia 12
HK - Hong Kong 11
RU - Federazione Russa 9
AU - Australia 8
TW - Taiwan 8
RO - Romania 6
NL - Olanda 5
PT - Portogallo 4
CZ - Repubblica Ceca 3
MX - Messico 3
NO - Norvegia 3
BR - Brasile 2
BY - Bielorussia 2
CH - Svizzera 2
GR - Grecia 2
ID - Indonesia 2
LT - Lituania 2
MY - Malesia 2
NG - Nigeria 2
PE - Perù 2
SA - Arabia Saudita 2
TH - Thailandia 2
UZ - Uzbekistan 2
AM - Armenia 1
AR - Argentina 1
EG - Egitto 1
EU - Europa 1
IL - Israele 1
KW - Kuwait 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MO - Macao, regione amministrativa speciale della Cina 1
PH - Filippine 1
PK - Pakistan 1
TN - Tunisia 1
Totale 5.182
Salva come PNG Salva come JPEG
Città #
Chandler 399
Beijing 316
Ann Arbor 215
Dublin 205
Houston 149
Fairfield 148
Torino 138
Ashburn 132
Wilmington 103
Jacksonville 102
Villeurbanne 89
Nyköping 85
Medford 72
Vienna 71
Woodbridge 71
Singapore 66
Princeton 62
Dearborn 61
Cambridge 58
Seattle 58
Turin 48
Fremont 45
Pisa 38
Warsaw 32
Shanghai 28
Boston 25
San Mateo 24
Pune 23
Dong Ket 21
Redwood City 21
Brussels 19
Norwalk 19
Boardman 17
Milan 16
Guangzhou 15
Nanjing 13
Tokyo 13
Rome 12
Chengdu 11
Hangzhou 11
Grafing 10
San Diego 10
Jülich 9
Toronto 9
Washington 9
Los Angeles 8
New York 8
Duncan 7
Santa Clara 7
Verona 7
Bologna 6
Hefei 6
Ottawa 6
Central 5
Düsseldorf 5
El Paso 5
Falls Church 5
Jinan 5
Lissone 5
Munich 5
Occimiano 5
Taipei 5
Tappahannock 5
Wuhan 5
Baotou 4
Changsha 4
Hebei 4
Kunming 4
Lachine 4
Lanzhou 4
London 4
Mountain View 4
Nanchang 4
Palermo 4
Phoenix 4
Raritan 4
Upper Marlboro 4
Valdagno 4
Zhengzhou 4
Ahmedabad 3
Aurora 3
Berlin 3
Buffalo 3
Catania 3
Chongqing 3
Genoa 3
Göttingen 3
Helsinki 3
Hull 3
Liverpool 3
Montréal 3
New Haven 3
Oslo 3
Philadelphia 3
Saint Petersburg 3
San Jose 3
Santa Monica 3
Seoul 3
Silver Spring 3
Trieste 3
Totale 3.331
Salva come PNG Salva come JPEG
Nome #
A theranostic approach based on the use of a dual boron/Gd agent to improve the efficacy of Boron Neutron Capture Therapy in the lung cancer treatment 374
Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells 362
p130Cas mediates the transforming properties of the anaplastic lymphoma kinase 243
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 236
The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation 224
Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors 210
Redundant and non-redundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice 182
Maternal immunization: New perspectives on its application against non-infectious related diseases in newborns 135
The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1. 124
Anaplastic lymphoma kinase in human cancer 115
The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL 109
Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin IgG and IgA secreting multiple myelomas 102
Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1 102
Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth. 99
Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. 99
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma 98
Detection of circulating tumor cells in multiple myeloma by a PCR-based method. 96
BRAF gene is not mutated in plasma cell leukemia and multiple myeloma 86
A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. 84
ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis 83
The mutation of N-ras oncogene does not involve myeloid and erythroid lineages in a case of multiple myeloma. 82
RhoA silencing reverts the resistance to doxorubicin in human colon cancer cells 80
Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation. 78
Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. 77
Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma. 76
NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells 73
Molecular purging of multiple myeloma cells by ex-vivo culture and retroviral transduction of mobilized-blood CD34+ cells 71
The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration 68
High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. 67
Liposomal doxorubicin reverses drug-resistance by inhibiting P-glycoprotein in human cancer cells 67
Development of a consensus IgH quantitative assay for the detection of minimal residual disease in Chronic Lymphocytic Leukemia using 3’-minor groove binder probes. 66
The anaplastic lymphoma kinase as an oncogene in solid tumors 66
Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. 64
PCR-detectable non-neoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis, but rare in subjects treated with chemotherapy. 63
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma 63
LIGHT/TNFSF14 Promotes Osteolytic Bone Metastases in Non-small Cell Lung Cancer Patients 62
Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer 61
Advances in cancer immunology and cancer immunotherapy 60
Targeting hif-1α regulatory pathways as a strategy to hamper tumor-microenvironment interactions in cll 60
The anaplastic lymphoma kinase in the pathogenesis of cancer 59
The battle against ALK resistance: successes and setbacks. 57
RHO Family GTPases in the Biology of Lymphoma 55
Modulation of doxorubicin resistance by the glucose 6-phosphate dehydrogenase activity 52
Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer 51
Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. 51
Simple and Rapid InVivo Generation of Chromosomal Rearrangements using CRISPR/Cas9 Technology 49
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. 48
Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells. 46
Modulation of doxorubicin resistance by the glucose 6-phosphate dehydrogenase activity 43
Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts 42
Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. 40
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. 38
The Tyrosine Phosphatase SHP2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration. 38
Modulation of doxorubicin resistance by the glucose 6-phosphate dehydrogenase activity 37
Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer 37
Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma 37
Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small- and large-scale Miltenyi cell sorting system. 34
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells 23
DNA repair mechanisms that promote insertion-deletion events during immunoglobulin gene diversification 20
Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases 16
Review: biological implications of oncogenic rearrangements in non-small cell lung cancer 14
Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma 11
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer 9
Regulation of CD45 phosphatase by oncogenic ALK in anaplastic large cell lymphoma 9
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia 7
Totale 5.390
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.594
article - articoli 0
book - libri 0
conference - conferenze 586
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.180
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020792 0 28 52 74 72 117 85 55 108 71 72 58
2020/2021662 42 48 62 27 67 31 50 32 77 99 53 74
2021/2022800 42 45 33 53 28 30 90 40 30 76 177 156
2022/20231.037 131 108 27 106 77 253 88 64 89 23 45 26
2023/2024499 64 80 34 28 40 80 6 38 7 34 32 56
2024/202552 14 38 0 0 0 0 0 0 0 0 0 0
Totale 5.390